Borko Jovanovic

9.1k total citations · 1 hit paper
118 papers, 6.0k citations indexed

About

Borko Jovanovic is a scholar working on Oncology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Borko Jovanovic has authored 118 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 26 papers in Pathology and Forensic Medicine and 21 papers in Molecular Biology. Recurrent topics in Borko Jovanovic's work include Lymphoma Diagnosis and Treatment (14 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Viral-associated cancers and disorders (7 papers). Borko Jovanovic is often cited by papers focused on Lymphoma Diagnosis and Treatment (14 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Viral-associated cancers and disorders (7 papers). Borko Jovanovic collaborates with scholars based in United States, United Kingdom and Italy. Borko Jovanovic's co-authors include David W. Hosmer, Stanley Lemeshow, Andrew M. Evens, Irene Helenowski, Mark J. Alberts, Raymond C. Bergan, P. S. Levy, Richard K. Burt, Bruce Brockstein and Leo I. Gordon and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Borko Jovanovic

116 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Best Subsets Logistic Regression

1989 1.1k citations Borko Jovanovic et al. profile →

Peers

Countries citing papers authored by Borko Jovanovic

Since Specialization

Citations

This map shows the geographic impact of Borko Jovanovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Borko Jovanovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Borko Jovanovic more than expected).

Fields of papers citing papers by Borko Jovanovic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Borko Jovanovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Borko Jovanovic. The network helps show where Borko Jovanovic may publish in the future.

Co-authorship network of co-authors of Borko Jovanovic

This figure shows the co-authorship network connecting the top 25 collaborators of Borko Jovanovic. A scholar is included among the top collaborators of Borko Jovanovic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Borko Jovanovic. Borko Jovanovic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma 2023 ·Blood Advances ·Jia Ruan, Jasmine M. Zain, (unknown), Borko Jovanovic, Xinlei Mi, Alok Swaroop, Jane N. Winter, Leo I. Gordon, Reem Karmali, Jonathan Moreira, Adam M. Petrich, Barbara Pro	19
2	A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases 2022 ·Clinical Breast Cancer ·Ami N. Shah, Cesar A. Santa‐Maria, Dhruvika Mukhija, Nikita Shah, (unknown), Priya Kumthekar, Kirsten B. Burdett, Shruti Chandra, Jenny C. Chang, (unknown), (unknown), Borko Jovanovic, Lorenzo Gerratana, William J. Gradishar, Massimo Cristofanilli	10
3	Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma 2018 ·Journal of Clinical Oncology ·Andrew M. Evens, Ranjana H. Advani, Irene Helenowski, Michelle A. Fanale, Sonali M. Smith, Borko Jovanovic, Gregory Bociek, Andreas K. Klein, Jane N. Winter, Leo I. Gordon, Paul A. Hamlin	96
4	Clinical outcomes with the MammoSite radiation therapy system: results of a prospective trial 2015 ·Journal of Radiation Oncology ·William Small, Tamer Refaat, Jonathan Strauss, Mahesh Gopalakrishnan, Kevin P. Bethke, Ellen B. Mendelson, Judith A. Wolfman, Borko Jovanovic, Krystyna Kiel	1
5	Mitogen-Activated Protein Kinase Kinase 4 (MAP2K4) Promotes Human Prostate Cancer Metastasis 2014 ·PLoS ONE ·Janet Pavese, Irene Ogden, (unknown), Xiaoke Huang, Li Xu, Borko Jovanovic, Raymond C. Bergan	35
6	A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma 2013 ·Annals of Oncology ·Andrew M. Evens, Kenneth R. Carson, Jill Kolesar, Chadi Nabhan, Irene Helenowski, Nahida Islam, Borko Jovanovic, Paul M. Barr, Paolo F. Caimi, S. A. Gregory, Leo I. Gordon	35
7	Patient knowledge and recall of health information following exposure to “facts and myths” message format variations 2013 ·Patient Education and Counseling ·Kenzie A. Cameron, Michael E. Roloff, Elisha M. Friesema, Tiffany L. Brown, Borko Jovanovic, (unknown), David W. Baker	46
8	Soy Isoflavone Supplementation for Breast Cancer Risk Reduction: A Randomized Phase II Trial 2012 ·Cancer Prevention Research ·Seema A. Khan, Robert T. Chatterton, (unknown), (unknown), Oukseub Lee, David Ivancic, Richard E. Heinz, Carola M. Zalles, Irene Helenowski, Borko Jovanovic, Adrian A. Franke, Maarten C. Bosland, Jun Wang, Nora Hansen, Kevin P. Bethke, Alexander Dew, (unknown), Raymond C. Bergan	126
9	Role of monocyte‐lineage cells in prostate cancer cell invasion and tissue factor expression 2010 ·The Prostate ·Paul F. Lindholm, Yi Lü, Brian P. Adley, (unknown), Borko Jovanovic, (unknown), Ximing J. Yang, (unknown)	24
10	The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial 2009 ·Clinical Cancer Research ·Andrew M. Evens, William G. Spies, Irene Helenowski, David R. Patton, Stewart Spies, Borko Jovanovic, (unknown), Elizabeth Hamilton, Daina Variakojis, Jun Chen, Louie Naumovski, Steven T. Rosen, Jane N. Winter, Richard Miller, Leo I. Gordon	15
11	Reduced Platelet Activity Is Associated With Early Clot Growth and Worse 3-Month Outcome After Intracerebral Hemorrhage 2009 ·Stroke ·Andrew M. Naidech, Borko Jovanovic, Storm M. Liebling, Rajeev Garg, Sarice L. Bassin, Bernard R. Bendok, Richard A. Bernstein, Mark J. Alberts, H. Hunt Batjer	142
12	MEK4 Function, Genistein Treatment, and Invasion of Human Prostate Cancer Cells 2009 ·JNCI Journal of the National Cancer Institute ·Li Xu, Yongzeng Ding, William J. Catàlona, Ximing J. Yang, W.F. Anderson, Borko Jovanovic, (unknown), (unknown), Xiaoke Huang, Karl A. Scheidt, Bruce Montgomery, Raymond C. Bergan	89
13	Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration 2009 ·Carcinogenesis ·Diana Romero, Aleksandra Terzic, Barbara A. Conley, Clarissa S. Craft, Borko Jovanovic, Raymond C. Bergan, Calvin Vary	32
14	Herpes Simplex Virus Hepatitis 2007 ·Liver Transplantation ·John P. Norvell, Andrés T. Blei, Borko Jovanovic, Josh Levitsky	154
15	Gene profiling of genistein’s effect in men with prostate cancer. 2006 ·Cancer Research ·Yongzeng Ding, Li Xu, Shan Chen, William J. Catàlona, David L. Kelly, Borko Jovanovic, Irene Helenowski, Ximing J. Yang, Michael Pins, Raymond C. Bergan	1
16	LY293111 Improves Efficacy of Gemcitabine Therapy on Pancreatic Cancer in a Fluorescent Orthotopic Model in Athymic Mice 2005 ·Neoplasia ·René Hennig, (unknown), Ralf Segersvärd, (unknown), Xianzhong Ding, Sambasiva M. Rao, Borko Jovanovic, Takeshi Iwamura, Marina Talamonti, Richard H. Bell, Thomas E. Adrian	46
17	Effect of LY293111 in combination with gemcitabine in colonic cancer 2004 ·Cancer Letters ·René Hennig, Xianzhong Ding, Weigang Tong, Richard C. Witt, Borko Jovanovic, Thomas E. Adrian	30
18	Risk Assessment for Inpatient Survival in the Long-term Acute Care Setting After Prolonged Critical Illness 2003 ·CHEST Journal ·Jane E. Dematte D’Amico, Helen K. Donnelly, (unknown), Joseph Feinglass, Borko Jovanovic, (unknown)	32
19	A Simple Analysis of Gene Expression and Variability in Gene Arrays Based on Repeated Observations 2001 ·PubMed ·Borko Jovanovic, Shuguang Huang, (unknown), (unknown), Raymond C. Bergan	13
20	A Look at the Rule of Three 1997 ·The American Statistician ·Borko Jovanovic, P. S. Levy	122

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact